These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

296 related items for PubMed ID: 25341043

  • 21. Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib.
    Luster TA, Carrell JA, McCormick K, Sun D, Humphreys R.
    Mol Cancer Ther; 2009 Feb; 8(2):292-302. PubMed ID: 19174554
    [Abstract] [Full Text] [Related]

  • 22. Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells.
    Baritaki S, Suzuki E, Umezawa K, Spandidos DA, Berenson J, Daniels TR, Penichet ML, Jazirehi AR, Palladino M, Bonavida B.
    J Immunol; 2008 May 01; 180(9):6199-210. PubMed ID: 18424742
    [Abstract] [Full Text] [Related]

  • 23. Combination of TRAIL with bortezomib shifted apoptotic signaling from DR4 to DR5 death receptor by selective internalization and degradation of DR4.
    Bychkov ML, Gasparian ME, Dolgikh DA, Kirpichnikov MP.
    PLoS One; 2014 May 01; 9(10):e109756. PubMed ID: 25310712
    [Abstract] [Full Text] [Related]

  • 24. TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window.
    Koschny R, Ganten TM, Sykora J, Haas TL, Sprick MR, Kolb A, Stremmel W, Walczak H.
    Hepatology; 2007 Mar 01; 45(3):649-58. PubMed ID: 17326159
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells.
    Li C, Li R, Grandis JR, Johnson DE.
    Mol Cancer Ther; 2008 Jun 01; 7(6):1647-55. PubMed ID: 18566236
    [Abstract] [Full Text] [Related]

  • 27. Bortezomib synergizes TRAIL-induced apoptosis in gastric cancer cells.
    Liu J, Qu XJ, Xu L, Zang Y, Qu JL, Hou KZ, Liu YP.
    Dig Dis Sci; 2010 Dec 01; 55(12):3361-8. PubMed ID: 20393880
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. General Sensitization of melanoma cells for TRAIL-induced apoptosis by the potassium channel inhibitor TRAM-34 depends on release of SMAC.
    Quast SA, Berger A, Buttstädt N, Friebel K, Schönherr R, Eberle J.
    PLoS One; 2012 Dec 01; 7(6):e39290. PubMed ID: 22723988
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Wogonin and related natural flavones overcome tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) protein resistance of tumors by down-regulation of c-FLIP protein and up-regulation of TRAIL receptor 2 expression.
    Ding J, Polier G, Köhler R, Giaisi M, Krammer PH, Li-Weber M.
    J Biol Chem; 2012 Jan 02; 287(1):641-649. PubMed ID: 22086925
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Targeted therapy of the XIAP/proteasome pathway overcomes TRAIL-resistance in carcinoma by switching apoptosis signaling to a Bax/Bak-independent 'type I' mode.
    Gillissen B, Richter A, Richter A, Overkamp T, Essmann F, Hemmati PG, Preissner R, Belka C, Daniel PT.
    Cell Death Dis; 2013 May 23; 4(5):e643. PubMed ID: 23703388
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs.
    Ganten TM, Haas TL, Sykora J, Stahl H, Sprick MR, Fas SC, Krueger A, Weigand MA, Grosse-Wilde A, Stremmel W, Krammer PH, Walczak H.
    Cell Death Differ; 2004 Jul 23; 11 Suppl 1():S86-96. PubMed ID: 15105837
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.